Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.  They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating the tumor microenvironment and tumor immunity.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Feb.  20, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Siegfried Reich, Ph.D. as executive vice president and chief scientific officer effective March 2. Dr. Reich has over 25 years of pharmaceutical and biotech experience developing more than 20 drug candidates, including the approved drugs Viracept® for HIV and the tyrosine kinase inhibitor Inlyta® for the treatment of kidney cancer.

Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer

SAN DIEGO, Jan.  23, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson has more than 30 years of pharmaceutical and biotech oncology experience, including as the former president of Pfizer oncology where he led its global oncology franchise.

Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

SAN DIEGO, Jan.  13, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today provided program updates for its four drug candidates and ongoing clinical studies.

Turning Point Therapeutics Announces Program Updates and Milestones for 2020

SAN DIEGO, Jan.  09, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that Dr. Jean Cui will step down as the company’s chief scientific officer for family reasons on Jan. 31. Dr. Cui will serve as a consultant and support the company during a transition period until June 30, 2020. She will remain on the company’s board of directors through her current term, which expires at the company’s 2020 annual meeting of stockholders.

Turning Point Therapeutics Announces Management Transition

SAN DIEGO, Jan.  06, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs.

Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs

Beyond Meat

Cortexyme Inc

IGM Biosciences Inc

Inmode Ltd

Karuna Therapeutics Inc

Nextcure

Palomar

Shockwave Medical

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who didn’t buy into the hype of more familiar names like Uber or Lyft.

Non-Household Names Topped the List of IPO Winners in 2019

Applied Therapeutics Inc

Aprea Therapeutics

BioNTech SE

Glaukos

Rapt Therapeutics Inc

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

These Were the 10 Best IPOs of 2019

Silk Road Medical Inc

Zoom Video

This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.

5 Best Performing IPOs of 2019

Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%

SAN DIEGO, Nov.  12, 2019  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate repotrectinib in pediatric patients with ALK-, NTRK- and ROS1-positive solid tumors.

Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

SAN DIEGO, Nov.  11, 2019  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its drug candidate TPX-0046 in patients with advanced solid tumors harboring RET genetic alterations.

Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor

Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q3 2019 Results - Earnings Call Transcript

News for Turning Point Therapeutics Stock (TPTX)